View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
March 22, 2019

Innovent doses first patient in Phase IIa trial of IBI306 to treat hypercholesterolemia

Innovent Biologics has announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI306, a recombinant anti-proprotein convertase substilisin/kexin type 9 (anti-PCSK9) monoclonal antibody, to treat hypercholesterolemia.

Innovent Biologics has announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI306, a recombinant anti-proprotein convertase substilisin/kexin type 9 (anti-PCSK9) monoclonal antibody, to treat hypercholesterolemia.

The placebo-controlled, double-blind, randomised, multiple ascending dose clinical trial is being conducted in China.

Under repeatedly different doses, the trial will evaluate the efficacy, tolerability, safety, as well as pharmacodynamics (PD) and pharmacokinetics (PK) profiles of IBI306.

“We hope IBI30, a recombinant fully human monoclonal antibody, will provide a better treatment option for patients with cardiovascular diseases.”

IBI306 binds to proprotein convertase substilisin/kexin type 9 (PCSK9) molecules. Furthermore, by reducing PCSK9-mediated low-density lipoprotein (LDL) receptor endocytosis, IBI306cuts down low-density lipoprotein cholesterol (LDL-C) levels.

Under the Phase I study, IBI306 preliminarily indicated good tolerability and acceptable safety profiles and offered prolonged dose-dependent reduction of LDL-C levels in healthy subjects.

The Phase IIa study will see enrollment of 60 patients with hypercholesterolemia.

Peking University First Hospital director of the department of pharmacy Yimin Cui said: “IBI306 was well tolerated and had an acceptable safety profile in the Phase I trial in healthy subjects. Furthermore, it reduces blood lipid levels in a dose-dependent manner. One unique feature of IBI306 is it can be potentially dosed with a long dosing interval. The results are encouraging.”

Innovent chairman, founder and CEO Michael Yu said: “IBI306 is a Category I biological innovative drug candidate developed by Innovent for the treatment of hypercholesterolemia. It has shown acceptable safety and good tolerability profile in Phase Ia study. We are looking forward to rapidly moving IBI306 into late-stage clinical development. We hope IBI306 can eventually benefit patients with cardiovascular diseases.”

Hypercholesterolemia is considered to be a grave issue in China as a result of unhealthy diet, lifestyles and aging population.

Dyslipidemia caused due to hypercholesterolemia is considered to be a major risk factor for cardiovascular mortality.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena